227 related articles for article (PubMed ID: 36289202)
1. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda.
Tumwebaze PK; Conrad MD; Okitwi M; Orena S; Byaruhanga O; Katairo T; Legac J; Garg S; Giesbrecht D; Smith SR; Ceja FG; Nsobya SL; Bailey JA; Cooper RA; Rosenthal PJ
Nat Commun; 2022 Oct; 13(1):6353. PubMed ID: 36289202
[TBL] [Abstract][Full Text] [Related]
2. Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine.
van Schalkwyk DA; Pratt S; Nolder D; Stewart LB; Liddy H; Muwanguzi-Karugaba J; Beshir KB; Britten D; Victory E; Rogers C; Millard J; Brown M; Nabarro LE; Taylor A; Young BC; Chiodini PL; Sutherland CJ
Clin Infect Dis; 2024 Feb; 78(2):445-452. PubMed ID: 38019958
[TBL] [Abstract][Full Text] [Related]
3. Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana.
Ahorhorlu SY; Quashie NB; Jensen RW; Kudzi W; Nartey ET; Duah-Quashie NO; Zoiku F; Dzudzor B; Wang CW; Hansson H; Alifrangis M; Adjei GO
Malar J; 2023 Feb; 22(1):58. PubMed ID: 36803541
[TBL] [Abstract][Full Text] [Related]
4.
Zhao W; Li X; Yang Q; Zhou L; Duan M; Pan M; Qin Y; Li X; Wang X; Zeng W; Zhao H; Sun K; Zhu W; Afrane Y; Amoah LE; Abuaku B; Duah-Quashie NO; Huang Y; Cui L; Yang Z
Front Cell Infect Microbiol; 2022; 12():1015957. PubMed ID: 36310880
[TBL] [Abstract][Full Text] [Related]
5. Changing Antimalarial Drug Sensitivities in Uganda.
Rasmussen SA; Ceja FG; Conrad MD; Tumwebaze PK; Byaruhanga O; Katairo T; Nsobya SL; Rosenthal PJ; Cooper RA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923866
[TBL] [Abstract][Full Text] [Related]
6.
Somé AF; Conrad MD; Kabré Z; Fofana A; Yerbanga RS; Bazié T; Neya C; Somé M; Kagambega TJ; Legac J; Garg S; Bailey JA; Ouédraogo J-B; Rosenthal PJ; Cooper RA
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0153423. PubMed ID: 38411062
[TBL] [Abstract][Full Text] [Related]
7. Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021.
Bakari C; Mandara CI; Madebe RA; Seth MD; Ngasala B; Kamugisha E; Ahmed M; Francis F; Bushukatale S; Chiduo M; Makene T; Kabanywanyi AM; Mahende MK; Kavishe RA; Muro F; Mkude S; Mandike R; Molteni F; Chacky F; Bishanga DR; Njau RJA; Warsame M; Kabula B; Nyinondi SS; Lucchi NW; Talundzic E; Venkatesan M; Moriarty LF; Serbantez N; Kitojo C; Reaves EJ; Halsey ES; Mohamed A; Udhayakumar V; Ishengoma DS
Malar J; 2024 Mar; 23(1):71. PubMed ID: 38461239
[TBL] [Abstract][Full Text] [Related]
8. Impact of parasite genomic dynamics on the sensitivity of Plasmodium falciparum isolates to piperaquine and other antimalarial drugs.
Wakoli DM; Ondigo BN; Ochora DO; Amwoma JG; Okore W; Mwakio EW; Chemwor G; Juma J; Okoth R; Okudo C; Yeda R; Opot BH; Cheruiyot AC; Juma D; Roth A; Ogutu BR; Boudreaux D; Andagalu B; Akala HM
BMC Med; 2022 Nov; 20(1):448. PubMed ID: 36397090
[TBL] [Abstract][Full Text] [Related]
9. Sustained
Amambua-Ngwa A; Okebe J; Mbye H; Ceesay S; El-Fatouri F; Joof F; Nyang H; Janha R; Affara M; Ahmad A; Kolly O; Nwakanma D; D'Alessandro U
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971859
[TBL] [Abstract][Full Text] [Related]
10. Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda.
Asua V; Vinden J; Conrad MD; Legac J; Kigozi SP; Kamya MR; Dorsey G; Nsobya SL; Rosenthal PJ
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559133
[TBL] [Abstract][Full Text] [Related]
11. Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda.
Balikagala B; Mita T; Ikeda M; Sakurai M; Yatsushiro S; Takahashi N; Tachibana SI; Auma M; Ntege EH; Ito D; Takashima E; Palacpac NM; Egwang TG; Onen JO; Kataoka M; Kimura E; Horii T; Tsuboi T
Malar J; 2017 Jan; 16(1):23. PubMed ID: 28068997
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of arps10, fd, pfmdr-2, pfcrt and pfkelch13 gene mutations in Plasmodium falciparum parasite population in Uganda.
Ocan M; Ashaba FK; Mwesigwa S; Edgar K; Kamya MR; Nsobya SL
PLoS One; 2022; 17(5):e0268095. PubMed ID: 35511795
[TBL] [Abstract][Full Text] [Related]
13. Drug susceptibility of
Tumwebaze PK; Katairo T; Okitwi M; Byaruhanga O; Orena S; Asua V; Duvalsaint M; Legac J; Chelebieva S; Ceja FG; Rasmussen SA; Conrad MD; Nsobya SL; Aydemir O; Bailey JA; Bayles BR; Rosenthal PJ; Cooper RA
Lancet Microbe; 2021 Sep; 2(9):e441-e449. PubMed ID: 34553183
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in Northern Uganda.
Fukuda N; Tachibana SI; Ikeda M; Sakurai-Yatsushiro M; Balikagala B; Katuro OT; Yamauchi M; Emoto S; Hashimoto M; Yatsushiro S; Sekihara M; Mori T; Hirai M; Opio W; Obwoya PS; Auma MA; Anywar DA; Kataoka M; Palacpac NMQ; Odongo-Aginya EI; Kimura E; Ogwang M; Horii T; Mita T
Parasitol Int; 2021 Apr; 81():102277. PubMed ID: 33370608
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of genetic markers associated with Plasmodium falciparum resistance to artemisinin-based combination therapy in Pakistan, 2018-2019.
Khan AQ; Pernaute-Lau L; Khattak AA; Luijcx S; Aydin-Schmidt B; Hussain M; Khan TA; Mufti FU; Morris U
Malar J; 2020 Jun; 19(1):206. PubMed ID: 32513171
[TBL] [Abstract][Full Text] [Related]
16. Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda.
Angwe MK; Mwebaza N; Nsobya SL; Vudriko P; Dralabu S; Omali D; Tumwebaze MA; Ocan M
PLoS One; 2024; 19(6):e0305064. PubMed ID: 38837973
[TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children.
Yeka A; Wallender E; Mulebeke R; Kibuuka A; Kigozi R; Bosco A; Kyambadde P; Opigo J; Kalyesubula S; Senzoga J; Vinden J; Conrad M; Rosenthal PJ
J Infect Dis; 2019 Mar; 219(7):1112-1120. PubMed ID: 30418593
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda.
Ebong C; Sserwanga A; Namuganga JF; Kapisi J; Mpimbaza A; Gonahasa S; Asua V; Gudoi S; Kigozi R; Tibenderana J; Bwanika JB; Bosco A; Rubahika D; Kyabayinze D; Opigo J; Rutazana D; Sebikaari G; Belay K; Niang M; Halsey ES; Moriarty LF; Lucchi NW; Souza SSS; Nsobya SL; Kamya MR; Yeka A
Malar J; 2021 Dec; 20(1):484. PubMed ID: 34952573
[TBL] [Abstract][Full Text] [Related]
19. Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in Senegal.
Delandre O; Daffe SM; Gendrot M; Diallo MN; Madamet M; Kounta MB; Diop MN; Bercion R; Sow A; Ngom PM; Lo G; Benoit N; Amalvict R; Fonta I; Mosnier J; Diawara S; Wade KA; Fall M; Fall KB; Fall B; Pradines B
Int J Antimicrob Agents; 2020 Dec; 56(6):106190. PubMed ID: 33045351
[TBL] [Abstract][Full Text] [Related]
20. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa.
Sisowath C; Petersen I; Veiga MI; Mårtensson A; Premji Z; Björkman A; Fidock DA; Gil JP
J Infect Dis; 2009 Mar; 199(5):750-7. PubMed ID: 19210165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
